細胞番号 : 細胞名
RCB0284 : Sq-1979
update : 2024/12/06
|
細胞特性(Comment:英) | Metastatic epithelial cell |
細胞特性(日) | 転移性のある腫瘍で、in vivo、in vitroで両用可能な細胞株。当室で脱マイコプラズマ汚染処理をしてある。 |
細胞特性(寄託者記述:英) | |
細胞特性(寄託者記述:日) | |
使用条件(英) | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
使用条件(日) | 基礎的研究につきましては、使用制限はありません。商業利用や特許取得を目的とする場合は、事前に必ず理研細胞バンクに連絡をすること。 |
備考(英) | |
備考(日) | |
提供申込書類(英) |
Order Form(C-0005.pdf)
 
MTA(C-0007.pdf)
 
MTA(C-0007p.pdf)
 
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
提供申込書類(日) |
依頼書C-0001.pdf
 
同意書(非営利学術目的)C-0003.pdf
 
同意書(営利目的)C-0003p.pdf
 
|
提供同意書は、使用機関の種類や目的に応じて、非営利学術目的 (C-XXXX) と営利目的 (C-XXXXp) の2種類があります。該当する提供同意書をご使用ください(詳細)。特許等の取得及び商業利用等は事前に必ず cellbank.brc@riken.jp までご連絡ください。
|
提供手数料 |
手数料とお支払いについてはこちらをご覧ください。 |
細胞基本情報
|
|
寄託者 |
Ando, Koichi
|
樹立者 |
Majima, Hideyuki
|
寄託日 |
1989
|
元の細胞 |
NR-S1
|
動物種 |
_mouse
< Mammals
|
動物系統名 |
C3H/He
|
採取組織 |
cheek
|
病名 |
carcinoma planoepitherial
|
細胞分類 |
cancer
|
入手歴 |
Mycoplasma was decontaminated
|
メモ_1 |
Mycoplasma was eliminated with MC-210.
|
|
細胞寿命 |
infinite
|
細胞形態 |
epithelial-like
|
Cellosaurus(Expasy) |
CVCL_6541
|
細胞培養・検査情報
| |
寄託時情報 |
ロット情報 |
培地・試薬情報 |
培地・試薬一覧はこちらをご覧ください。 |
|
培養形態 |
|
Adherent cells
|
培地 |
|
MEM + 10% FBS
|
抗生物質 |
|
Free
|
|
継代方法 |
|
0.25% Trypsin
|
|
継代密度 |
|
1 : 8 split
|
継代・培地交換頻度 |
|
Subculture : 2 times/week
|
培養最適温度 |
|
37
℃
|
二酸化炭素濃度 |
|
5
%
|
凍結培地 |
|
Medium + 10% DMSO
|
凍結方法 |
|
Slow freezing
|
マイコプラズマ/アコレプラズマ |
|
(-)
|
マウス系統検査 |
|
OK
|
アイソザイム検査 |
|
LD, NP
|
画像情報 |
寄託時情報 | ロット情報 |
|
|
文献情報 |
Reference(英) |
1件
|
Reference(日) |
0件
|
利用者成果(英) |
12件
|
利用者成果(日) |
0件
|
利用者成果(英) |
21629
Machida T, Sakuma K, Fuwa N, Tanaka A.
Local Low-dose Anti-PD-L1 Antibodies Improve Antitumor Effects in Oral Squamous Cell Carcinoma.
Anticancer Res
2024
44(3):993-1002
PubMed ID: 38423636
DOI: 10.21873/anticanres.16894
|
17186
Sakuma K, Kii T, Takahashi H, Suzuki S, Yoshikawa K, Ogawa T, Tanaka A.
An In Vivo Study of Local Administration of Low-dose Anti-PD-1 Antibody Using an Oral Cancer Cell Line
Anticancer Res
2022
42(9):4293-4303
PubMed ID: 36039414
DOI: 10.21873/anticanres.15929
|
20961
Horii T, Orikawa Y, Ohira Y, Eta R, Kobayashi N, Sato T, Watanabe T, Tanaka T.
Potential of Z-100, extracted from Mycobacterium tuberculosis strain Aoyama B, as a hot tumor inducer.
Cancer Cell Int
2022
22(1):392
PubMed ID: 36494701
DOI: 10.1186/s12935-022-02821-6
|
20202
Matsunami A, Mizuno-Kamiya M, Kawaki H, Takayama E, Ueno K, Ando M, Morimoto-Ito H, Muramatsu Y, Sumitomo S, Kondoh N.
Augmented secretion of IL-1α from mouse oral squamous cell carcinoma (OSCC) cells caused by serum deprivation and hypoxia promotes immune suppressive activity of mesenchymal stromal cells.
J Oral Biosci
2021
PubMed ID: 34153475
DOI: 10.1016/j.job.2021.06.001
|
11681
Hiroe Morimoto-Ito, Masako Mizuno-Kamiya, Naoki Umemura, Yoshinori Inagaki, Eiji Takayama, Harumi Kawaki, Yasunori Muramatsu, Shinichiro Sumitomo, Nobuo Kondoh
Immunosuppressive Effect of Mesenchymal Stromal Cells is Enhanced by IL-1α from Oral Squamous Cell Carcinoma Cells
The Open Dentistry Journal
2019
13:221-227
DOI: 10.2174/1874210601913010221
|
10705
Adachi M, Mizuno-Kamiya M, Takayama E, Kawaki H, Inagaki T, Sumi S, Motohashi M, Muramatsu Y, Sumitomo SI, Shikimori M, Yamazaki Y, Kondoh N.
Gene expression analyses associated with malignant phenotypes of metastatic sub-clones derived from a mouse oral squamous cell carcinoma Sq-1979 cell line.
Oncol Lett
2018
15:3350-3356
PubMed ID: 29435078
DOI: 10.3892/ol.2017.7648
|
11047
Suppressive effect of mesenchymal stromal cells on interferon-γ-producing capability of spleen cells was specifically enhanced through humoral mediator(s) from mouse oral squamous cell carcinoma Sq-1979 Cells In Vitro
Cancer Translational Medicine
2018
4, 9-16
DOI: 10.4103/ctm.ctm_34_17
|
11026
The producing capabilities of Interferon-γ and Interleukin-10 of spleen cells in primary and metastasized oral squamous cell carcinoma cells-implanted mice
Cancer Transl Med
2017
3:194–9
DOI: 10.4103/ctm.ctm_30_17
|
14354
Sumi S, Umemura N, Takayama E, Ohkoshi E, Adachi M, Mizuno-Kamiya M, Inagaki T, Kawaki H, Sumitomo S, Kondoh N.
Metastasized murine oral squamous cell carcinoma cells induce intratumoral polymorphonuclear myeloid derived suppressor cells
Oncol Rep
2017
37(5):2897-2904
PubMed ID: 28405677
DOI: 10.3892/or.2017.5575
|
18749
Li X, Bukawa H, Hirota M, Tsuyuki Y, Omura S, Fujita K.
Novel OK-432-conjugated tumor vaccines induce tumor-specific immunity against murine tongue cancer
J Dent Res
2003
82(8):636-4
PubMed ID: 12885850
DOI: 10.1177/154405910308200813
|
17923
Matsumoto K, Saga Y, Ikemura T, Sakakura T, Chiquet-Ehrismann R.
The distribution of tenascin-X is distinct and often reciprocal to that of tenascin-C
J Cell Biol
1994
125(2):483-93
PubMed ID: 7512972
DOI: 10.1083/jcb.125.2.483
|
17890
Saga Y, Tsukamoto T, Jing N, Kusakabe M, Sakakura T.
Murine tenascin: cDNA cloning, structure and temporal expression of isoforms
Gene
1991
104(2):177-85
PubMed ID: 1717349
DOI: 10.1016/0378-1119(91)90248-a
|